QLP-31907

Primary Objectives (Phase Ia - Dose Escalation): To determine the maximum tolerated dose (MTD)/recommended dose for Phase Ib and subsequent trials of PSB202 in patients with previously treated B-cell malignancies (specifically indolent/follicular B-cell non-Hodgkin lymphoma [NHL], CLL, and Waldenstrom's macroglobulinemia [WM]). Primary Objectives (Phase Ib - Dose Expansion): To evaluate the anti-tumor activity of PSB202 based on ORR (as assessed by investigator). Secondary Objectives (Phase Ia - Dose Escalation): To determine the safety profile and tolerability of PSB202. To determine the pharmacokinetic (PK) and pharmacodynamic (PD) properties of PSB202. To evaluate the preliminary anti-tumor activity of PSB202 based on the investigator-assessed overall response rate (ORR). Secondary Objectives (Phase Ib - Dose Expansion): To preliminarily evaluate the anti-tumor activity of PSB202; To determine the safety profile and tolerability of PSB202. Determine the PK/PD characteristics of PSB202 to form evidence of its biological impact Exploratory objectives (Phase Ia): Determine the relationship between PK and drug effects (including efficacy and safety). Exploratory objectives (Phase Ia and Phase Ib): In patients who achieve a clinical response (CR), evaluate minimal residual disease (MRD) in peripheral blood and/or bone marrow by molecular testing; in patients with FL: determine the reversal characteristics of BCL-2 rearrangements in peripheral blood.